Altimmune Ties Alcohol-Trial Timing To Funding That Would Avoid Issuing More Shares
A December FDA meeting will help define the proposed program, while existing resources are expected to cover the MASH readout in 2029.
Altimmune, which develops treatments for serious liver diseases, tied its proposed late-stage alcohol-use-disorder trial’s timing to regulatory feedback and financing on Thursday’s earnings call. Chief Executive Officer Jerry Durso said the company would first use its December FDA meeting to help define the study before settling on funding.
Funding Before A Start Date
“Our preference remains to pursue non-dilutive funding for the program,” Chief Financial Officer Greg Weaver said on the call. The options include royalty debt or a strategic partnership—ways to finance development without issuing additional shares.
Asked by a B. Riley analyst whether the trial could begin in the first half of next year, Durso stressed both speed and financing that serves the program and shareholders. “We're not at a point where we're going to guide specifically on timing,” he said.
Altimmune ended September with $480 million in cash, cash equivalents and investments, according to its Thursday results release. Weaver expects existing resources to support operations through the anticipated 2029 readout from its late-stage trial in metabolic dysfunction-associated steatohepatitis, or MASH, a metabolic liver disease. Regulatory discussions should clarify the alcohol program’s size and cost, he said.
Testing Drinking And Liver Benefits
Pemvidutide, Altimmune’s investigational weekly injection, activates glucagon and GLP-1 receptors. The company has no products approved for sale and is testing the drug across MASH, alcohol use disorder and alcohol-associated liver disease.
The company announced alcohol-study results in July. Weekly heavy-drinking days fell by 4.20 days with pemvidutide, compared with 2.75 days for placebo; participants also received behavioral intervention.
Chief Medical Officer Christophe Arbet-Engels said on the call that the proposed pivotal study would target moderate to severe alcohol use disorder, including patients with advanced liver impairment. Management proposes testing 1.8-milligram and 2.4-milligram doses, with gradual dose increases.
The proposed main measure would assess drinking-risk levels, with freedom from heavy-drinking days as a key secondary measure. Drinking benefits would be assessed at 26 weeks, with follow-up extending to one year for additional safety and efficacy data. The final design remains subject to regulatory discussions.
Liver Trials Raise Development Spending
Altimmune began its late-stage MASH trial in July. Its mid-stage alcohol-associated liver disease study has completed enrollment, with results expected in the second half of 2027.
Third-quarter research spending rose to $27.0 million from $15.0 million a year earlier. The company attributed the increase primarily to those MASH and alcohol-associated liver disease trials; $20.3 million went toward direct pemvidutide development costs.
Administrative expenses increased to $8.7 million from $5.9 million, primarily because of compensation and professional services, the company said. Its net loss widened to $31.6 million from $19.0 million, while the per-share loss was $0.15 versus $0.21.
Durso expects to communicate the FDA discussion’s outcome after receiving meeting minutes, which typically arrive within 30 days. Management also anticipates European regulatory dialogue in the first quarter.
Sources
- Altimmune results release (Form 8-K, EX-99.1) — SEC EDGAR
- Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder - BioSpace — biospace.com
- Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology — Yahoo Finance
- Altimmune's Pemvidutide Meets Primary Endpoint in Phase 2 Alcohol Use Disorder Trial — Yahoo Finance
- Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder — Yahoo Finance
- Altimmune Announces Third Quarter 2026 Financial Results — globenewswire.com